Cell Lysis and Fractionation Global Market Report 2024

The cell lysis and fractionation market size has grown strongly in recent years. It will grow from $3.14 billion in 2023 to $3.42 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The expansion during the historical period can be credited to the rise in investments in life science research, heightened emphasis on personalized medicine, widespread occurrence of diseases, technological progressions in cell lysis and fractionation techniques, and the increasing demand for biopharmaceuticals and biotechnology products.

The cell lysis and fractionation market size is expected to see strong growth in the next few years. It will grow to $4.57 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The expansion anticipated in the forecast period is driven by a heightened focus on personalized medicine, augmented government funding for research, substantial demand for efficient cell lysis and fractionation techniques, technological advancements in genomics and proteomics, and an escalating prevalence of chronic and infectious diseases. Significant trends expected in the forecast period encompass sustained growth in the adoption of personalized medicine methodologies, greater incorporation of automation and robotics in lysis and fractionation procedures, broadening applications in clinical diagnostics and drug development, advancements in microfluidics and lab-on-a-chip technologies for cell analysis, and an increased emphasis on point-of-care and decentralized testing solutions.

The increasing emphasis on personalized medicine is poised to drive significant growth within the cell lysis and fractionation markets in the coming years. Personalized medicine, an evolving medical approach, leverages an individual's genetic profile to diagnose and treat diseases effectively. It entails tailoring medical decisions and therapies to each patient's unique characteristics, particularly focusing on their genetic makeup. Cell lysis and fractionation serve as fundamental components of precision medicine, enabling the isolation and analysis of specific subcellular components from patient samples, including proteins, organelles, and nucleic acids. This capability empowers scientists and healthcare professionals to delve into the molecular mechanisms underlying diseases and develop personalized treatments based on each patient's distinct molecular traits. Notably, the Personalized Medicine Coalition (PMC) projects a significant rise in the availability of genetic testing products and personalized medicines across various disease categories, further underscoring the pivotal role of personalized medicine in shaping the landscape of healthcare. Consequently, the increasing emphasis on personalized medicine emerges as a primary driver propelling the expansion of the cell lysis and fractionation markets.

Key players within the cell lysis and fractionation markets are actively pursuing the introduction of advanced solutions to gain a competitive edge in the evolving landscape. One such innovation is exemplified by the development of CGT (cell and gene therapy) viral vector lysis kits, designed to streamline viral vector lysis processes and enhance workflow standardization and safety. These kits offer a simplified methodology for Adeno-associated virus (AAV) lysis, facilitating precise quantification of virus titers across multiple serotypes from cell lysates. For instance, QIAGEN, a leading provider of sample and assay technologies, launched the CGT Viral Vector Lysis Kit in July 2023, aimed at enabling precise and uniform virus titer quantification for various serotypes. Complementing QIAGEN's extensive digital PCR portfolio for the biopharmaceutical industry, this innovative solution underscores the company's commitment to advancing cell lysis and fractionation technologies to meet the evolving demands of the market. By providing robust and standardized solutions for viral vector lysis, companies such as QIAGEN are poised to play a pivotal role in facilitating the broader adoption of personalized medicine and driving growth within the cell lysis and fractionation markets.

In December 2022, MilliporeSigma, a pharmaceutical company based in the United States, finalized the acquisition of Erbi Biosystems Inc. for an undisclosed sum. Through this strategic move, MilliporeSigma aims to bolster its portfolio and expertise in the bioreactors and cell culture technologies sector. Erbi Biosystems is renowned as the developer of the Breez platform technology, a 2 ml micro-bioreactor platform known for its micro-scale, fully automated, and functionally closed system. Erbi Biosystems Inc., based in the United States, specializes in providing microfluidic solutions designed to facilitate efficient and controlled cell lysis and fractionation..

Major companies operating in the cell lysis and fractionation market report are Hoffmann-La Roche Ltd, Merck & Co. Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Lonza Group AG, Illumina Inc., Beckman Coulter Inc., PerkinElmer Inc., IDEX Corporation, Bio-Rad Laboratories Inc., QIAGEN NV, Eppendorf AG, Miltenyi Biotec B.V. & Co. KG, Promega Corporation, Takara Bio Inc., Abcam plc, Cell Signaling Technology Inc., BioVision Inc., Diagenode LLC, Claremont BioSolutions LLC, Norgen Biotek Corp., Qsonica LLC, Labfreez Instruments Group Co. Ltd.

North America was the largest region in the cell lysis and fractionation market in 2023. The regions covered in the cell lysis and fractionation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell lysis and fractionation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cell lysis and fractionation are interconnected methods utilized in biological research to rupture cells and segregate their constituents for analysis. Cell lysis involves disintegrating a cell to discharge its contents, comprising proteins, nucleic acids, and additional biological elements. Conversely, fractionation entails segregating cellular components based on their size, shape, density, charge, or other attributes.

The primary types of cell lysis and fractionation involve mammalian cells and microbial cells. Mammalian cells are eukaryotic cells derived from mammals, commonly used in cell culture and the biomanufacturing of therapeutic proteins and viral vaccines. These cells find applications in various processes such as nucleic acid and protein purification, and are utilized by research laboratories, institutes, biopharmaceutical, and biotechnology companies.

The cell lysis and fractionation market research report is one of a series of new reports that provides cell lysis and fractionation market statistics, including cell lysis and fractionation industry global market size, regional shares, competitors with cell lysis and fractionation market share, detailed cell lysis and fractionation market segments, market trends, and opportunities, and any further data you may need to thrive in the cell lysis and fractionation industry. This cell lysis and fractionation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cell lysis and fractionation market consists of revenues earned by entities by providing cellular contents extraction, cytoplasmic separation, and cell disruption. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell lysis and fractionation market also includes sales of cell lysis instruments, cell lysis reagents, and consumables. Values in this market are ‘factory gate’ values, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.